Ultrafast laser technology continues to surprise. While research in this field may seem rather abstract at first glance, it very often leads to concrete applications. This is particularly… read more.
Women 50 or older who de-escalated to less-frequent mammography three years after curative surgery for early-stage breast cancer had similar outcomes to women who received annual mammography, according… read more.
Bristol-Myers Squibb K.K. announced that the company has received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma (idecabtagene vicleucel), a… read more.
Breast cancer mortality is significantly reduced when women regularly attend screening mammograms, according to research being presented today at the annual meeting of the Radiological Society of North America (RSNA)…. read more.
Redispensing cancer drugs reduces both environmental impact and medical costs, according to research from Radboudumc pharmacy published in JAMA Oncology. The annual savings could amount to tens of millions…. read more.
Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of subcutaneous (SC, or under the skin). Tecentriq (atezolizumab)…. read more.
Patients undergoing radiation therapy for certain types of cancer at Henry Ford West Bloomfield Hospital are among the first in the country with access to a cutting-edge treatment system that… read more.
New materials developed at the University of Surrey could pave the way for a new generation of flexible X-ray detectors, with potential applications ranging from cancer treatment to… read more.
Mirati Therapeutics, Inc. a commercial stage biotechnology company, announced the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization approval for Krazati (adagrasib) as… read more.
Women who get a false-positive mammogram reading are more likely to develop breast cancer over the ensuing 20 years, researchers reported on Nov. 2, 2023 in JAMA Oncology. As… read more.
Eli Lilly and Company announced five-year outcomes from a pre-planned analysis of the Phase III monarchE study evaluating two years of adjuvant Verzenio (abemaciclib) in combination with endocrine… read more.
In patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus standard-treatment leuprolide is superior to leuprolide monotherapy for metastasis-free survival. And enzalutamide monotherapy is also superior to… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
